Immunic, Inc. Approves 1-for-10 Reverse Stock Split, Effective April 27

summarizeSummary

Immunic, Inc. stockholders approved a reverse stock split, and the Board subsequently set the ratio at 1-for-10, effective April 27, 2026, to address Nasdaq listing requirements.

check_boxKey Events

• Stockholders Authorize Reverse Split

  At a Special Meeting, stockholders approved a proposal to authorize the Board to amend the company's charter to effect a reverse stock split at a ratio between 1-for-10 and 1-for-30. The proposal passed with 57,404,749 votes For, 12,594,555 Against, and 623,363 Abstentions.

• Board Approves 1-for-10 Reverse Stock Split

  Following stockholder authorization, the Board approved a 1-for-10 reverse stock split of the company's common stock.

• Effective Date Set

  The reverse stock split is expected to become effective at 12:01 a.m. Eastern Time on April 27, 2026, with post-split shares beginning to trade on Nasdaq under the existing 'IMUX' symbol on the same day.

auto_awesomeAnalysis

Immunic, Inc. has finalized its plan for a reverse stock split, a significant corporate action often undertaken to increase share price and meet exchange listing requirements. While this move addresses the Nasdaq minimum bid price rule, which the company recently regained compliance with, reverse splits are generally viewed negatively by the market as they can signal underlying financial challenges or a struggle to maintain investor confidence. Investors should note that while the share price will increase, the total value of their holdings will remain the same immediately after the split, as the number of shares will decrease proportionally. This action follows the company's previous disclosures regarding a proposed reverse stock split in its 10-K and recent Nasdaq compliance efforts.